Dermata Therapeutics, Inc. SEC filings DRMA
Dermata Therapeutics, Inc. has 371 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Oct 21, 2026 | — |
| S-3 | Shelf registration | Oct 9, 2026 | — |
| S-8 | Employee stock plan registration | Jun 4, 2026 | — |
| 424B3 | Prospectus | May 29, 2026 | — |
| S-3/A | Filing | May 22, 2026 | — |
| 424B3 | Prospectus | Jan 29, 2026 | — |
| 424B5 | Prospectus supplement | Jan 27, 2026 | — |
| S-3 | Shelf registration | Jan 22, 2026 | — |
| S-3 | Shelf registration | Nov 24, 2025 | — |
| 424B5 | Prospectus supplement | Nov 7, 2025 | — |
| 424B3 | Prospectus | Apr 23, 2025 | — |
| S-3 | Shelf registration | Apr 15, 2025 | — |
| 424B3 | Prospectus | Feb 5, 2025 | — |
| S-3 | Shelf registration | Jan 30, 2025 | — |
| 424B3 | Prospectus | Sep 24, 2024 | — |
| S-3 | Shelf registration | Sep 19, 2024 | — |
| S-8 | Employee stock plan registration | Aug 7, 2024 | — |
| 424B5 | Prospectus supplement | Aug 2, 2024 | — |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| 424B5 | Prospectus supplement | Jun 7, 2024 | — |
| 424B3 | Prospectus | Dec 15, 2023 | — |
| S-3 | Shelf registration | Dec 7, 2023 | — |
| S-8 | Employee stock plan registration | Sep 14, 2023 | — |
| 424B4 | Prospectus | Jul 27, 2023 | — |
| S-1 | Registration statement | Jul 7, 2023 | — |
| 424B5 | Prospectus supplement | May 25, 2023 | — |
| 424B3 | Prospectus | Mar 21, 2023 | — |
| 424B4 | Prospectus | Mar 20, 2023 | — |
| S-1/A | Amended registration statement | Mar 16, 2023 | — |
| S-1/A | Amended registration statement | Mar 15, 2023 | — |
| S-1/A | Amended registration statement | Mar 13, 2023 | — |
| S-1 | Registration statement | Mar 1, 2023 | — |
| S-3 | Shelf registration | Nov 15, 2022 | — |
| S-8 | Employee stock plan registration | Aug 26, 2022 | — |
| 424B3 | Prospectus | Jun 24, 2022 | — |
| 424B3 | Prospectus | May 19, 2022 | — |
| 424B4 | Prospectus | May 13, 2022 | — |
| S-1 | Registration statement | May 4, 2022 | — |
| S-1/A | Amended registration statement | Feb 7, 2022 | — |
| FWP | Free writing prospectus | Feb 4, 2022 | — |
| S-1 | Registration statement | Feb 4, 2022 | — |
| S-8 | Employee stock plan registration | Dec 10, 2021 | — |
| 424B3 | Prospectus | Sep 1, 2021 | — |
| 424B4 | Prospectus | Aug 16, 2021 | — |
| S-1MEF | Filing | Aug 12, 2021 | — |
| S-1/A | Amended registration statement | Aug 6, 2021 | — |
| FWP | Free writing prospectus | Jul 12, 2021 | — |
| S-1/A | Amended registration statement | Jul 9, 2021 | — |
| S-1/A | Amended registration statement | Jul 2, 2021 | — |
| S-1 | Registration statement | Jun 10, 2021 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.